Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8763095 | 0.87 | ALDH1A1 (0.39) | TSHRCYP1A2TDP1KDM4ECYP2A6 | |
| SCHEMBL956341 | 0.85 | ALDH1A1 (0.43) | TSHRCYP1A2TDP1KDM4ECYP2A6 | |
| SCHEMBL30755316 | 0.85 | ALDH1A1 (0.43) | TSHRCYP1A2TDP1KDM4ECYP2A6 | |
| SCHEMBL3075207 | 0.85 | TRPA1 (0.45) | TSHRCYP1A2TDP1KDM4EEGFR | |
| SCHEMBL20249844 | 0.85 | ACHE (0.43) | TSHRTDP1KDM4EACHEALDH1A1 | |
| SCHEMBL28886003 | 0.85 | CD44 (0.45) | TSHRCYP1A2TDP1KDM4ECYP2A6 | |
| SCHEMBL11114860 | 0.85 | TAAR1 (0.38) | TSHRKDM4EALDH1A1TAAR1MEN1 | |
| SCHEMBL31459480 | 0.85 | ACHE (0.43) | TSHRTDP1KDM4EACHEALDH1A1 | |
| SCHEMBL31459423 | 0.85 | TAAR1 (0.38) | TSHRKDM4EALDH1A1TAAR1MEN1 | |
| SCHEMBL16888337 | 0.79 | ALDH1A1 (0.38) | TSHRCYP1A2TDP1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006321-B2 | Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-06-11 | — | — | US | disclosed |
| US-20230225201-A1 | Organic Light Emitting Diode and Device Comprising the Same | NOVALED GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
| US-11691938-B2 | Process for preparing 2,6-dialkylphenylacetic acids | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
| US-11691938-B2 | Process for preparing 2,6-dialkylphenylacetic acids | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
| US-11691938-B2 | Process for preparing 2,6-dialkylphenylacetic acids | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
| US-20230037225-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS APELIN RECEPTOR AGONISTS | Sanford Burnham Prebys Medical Discovery Institute | 2023-02-02 | — | — | US | disclosed |
| US-20230037225-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS APELIN RECEPTOR AGONISTS | Sanford Burnham Prebys Medical Discovery Institute | 2023-02-02 | — | — | US | disclosed |
| WO-2022222911-A1 | PYRIMIDONE COMPOUND AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-10-27 | — | — | WO | disclosed |
| CN-115215862-A | Pyrimidone compounds and uses thereof | 武汉人福创新药物研发中心有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-11345705-B2 | Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-05-31 | — | — | US | disclosed |
| US-6441237-B1 | DRUGS; ANTIARRHTHYMIA AGENTS, ANTIISCHEMIC AGENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-08-27 | — | — | US | disclosed |
| CN-1083452-C | Pyrido (2, 3 -d) pyrimidines for inbibiting protein tyrosine kinase mediated cellular proliferation | WARNER LAMBERT CO (US) | 2002-04-24 | — | — | CN | disclosed |
| EP-1154983-A1 | NOVEL SUBSTITUTED 3-PHENOXY AND 3-PHENYLALKYLOXY-2-PHENYL-PROPYLAMINES | Boehringer Ingelheim Pharma KG (DE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000048987-A1 | NOVEL SUBSTITUTED 3-PHENOXY AND 3-PHENYLALKYLOXY-2-PHENYL-PROPYLAMINES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-08-24 | — | — | WO | disclosed |
| US-5945422-A | ANTICANCER AGENTS; ATHEROSCLEROSIS; RESTENOSIS; PSORIASIS | WARNER-LAMBERT COMPANY (US) | 1999-08-31 | — | — | US | disclosed |
| CN-1183099-A | Pyrido [2, 3-d ] pyrimidines for inhibiting protein tyrosine kinase mediated cell proliferation | WARNER LAMBERT CO (US) | 1998-05-27 | — | — | CN | disclosed |
| US-5733914-A | Pyrido 2, 3-d!pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation | WARNER-LAMBERT COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| EP-0823908-A1 | PYRIDO 2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1998-02-18 | — | — | EP | disclosed |
| US-5620981-A | ANTICARCINOGENIC AGENTS, ATHEROSCLEROSIS, RESTENOSIS, PSORIASIS | WARNER-LAMBERT COMPANY (US) | 1997-04-15 | — | — | US | disclosed |
| WO-1996034867-A1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345705-B2 | Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists | APLNR, AP3B1, AGTR1 | TSHR 349/4885CYP1A2 2146/4885TDP1 1348/4885 |
| US-20230037225-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS APELIN RECEPTOR AGONISTS | APLNR, AP3B1, AGTR1 | TSHR 349/4885CYP1A2 2146/4885TDP1 1348/4885 |
| US-12006321-B2 | Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists | APLNR, AP3B1, AGTR1 | TSHR 349/4885CYP1A2 2146/4885TDP1 1348/4885 |
| US-11691938-B2 | Process for preparing 2,6-dialkylphenylacetic acids | ADH1C, ADH1A, ADH5 | TSHR 4521/4885CYP1A2 43/4885TDP1 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.